Ghent, Belgium – 6 September 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Firm” or “Sequana Medical“), a pioneer within the remedy of fluid overload in liver illness, coronary heart failure and most cancers, will announce its half-year outcomes ended 30 June 2023 on Thursday, 14 September 2023.

The administration crew will host a convention name with stay webcast at 03:00 pm CEST / 09:00 am EST on the day of the outcomes.

The webcast could be accessed by registering on the Buyers occasion web page of Sequana Medical’s web site or by clicking right here. To take part within the Q&A, please click on right here to register. As soon as registered, you’ll obtain dial-in numbers and a affirmation code. The webcast and convention name will probably be carried out in English and a replay will probably be out there on the Firm’s web site shortly thereafter.

For extra info, please contact:

Sequana Medical

Lies Vanneste
Director Investor Relations
E: [email protected]
T: +32 (0)498 053579

About Sequana Medical

Sequana Medical NV is a pioneer in treating fluid overload, a critical and frequent medical complication in sufferers with liver illness, coronary heart failure and most cancers. These sufferers can have as much as 15 liters of additional fluid of their our bodies, inflicting main medical points together with elevated mortality, repeated hospitalizations, extreme ache, problem respiration and restricted mobility that severely impacts day by day life. Though diuretics are commonplace of care, the issue is that in lots of sufferers they’re not efficient and / or tolerable. There are restricted efficient remedy choices for these sufferers, leading to poor medical outcomes, excessive prices and a serious affect on their high quality of life. Sequana Medical is searching for to supply modern remedy choices for this huge and rising “diuretic-resistant” affected person inhabitants.

alfapump® and DSR® are Sequana Medical’s proprietary platforms that work with the physique to deal with diuretic-resistant fluid overload, delivering main medical and high quality of life advantages for sufferers and lowering prices for healthcare methods. The Firm has reported constructive major endpoint knowledge from the North American pivotal POSEIDON trial of the alfapump in recurrent or refractory ascites attributable to liver cirrhosis, enabling the submitting of a Pre-Market Approval (PMA) utility with the FDA, deliberate for This autumn 2023. Having delivered medical proof-of-concept for DSR as a disease-modifying drug program for the remedy of coronary heart failure, the Firm has commenced MOJAVE, a US randomized managed multi-center Part 1/2a medical trial of DSR 2.0, with preliminary knowledge anticipated in This autumn 2023.

Story continues

Sequana Medical is listed on Euronext Brussels (Ticker: SEQUA.BR) and headquartered in Ghent, Belgium. For additional info, please go to www.sequanamedical.com.

Essential Regulatory Disclaimers

The alfapump® system is at present not accredited in america or Canada. In america and Canada, the alfapump system is at present underneath medical investigation (POSEIDON Trial) and is being studied in grownup sufferers with refractory or recurrent ascites attributable to liver cirrhosis. DSR® remedy remains to be in growth and it needs to be famous that any statements relating to security and efficacy come up from ongoing pre-clinical and medical investigations which have but to be accomplished. There is no such thing as a hyperlink between DSR remedy and ongoing investigations with the alfapump system in Europe, america or Canada.

Be aware: alfapump® and DSR® are registered trademarks.

Ahead-looking statements

This press launch could include predictions, estimates or different info that is perhaps thought-about forward-looking statements.
Such forward-looking statements usually are not ensures of future efficiency. These forward-looking statements signify the present judgment of Sequana Medical on what the long run holds, and are topic to dangers and uncertainties that might trigger precise outcomes to vary materially. Sequana Medical expressly disclaims any obligation or enterprise to launch any updates or revisions to any forward-looking statements on this press launch, besides if particularly required to take action by regulation or regulation. You shouldn’t place undue reliance on forward-looking statements, which replicate the opinions of Sequana Medical solely as of the date of this press launch.

Attachments